[ET Net News Agency, 4 February 2021] Daiwa Research lifted its target price for Ping
An Healthcare and Technology (PA Good Doctor) (01833) to HK$117 from HK$100 and reaffirmed
its "outperform" rating.
The research house said PA Good Doctor's analyst briefing provided more clarity on its
strategies for the next few years. In addition to its existing "2C" channels, through O2O
synergies from Ping An Insurance Group, Daiwa expects PA Good Doctor to capitalise on its
"2B" corporate customers channel and insurance channel.
Daiwa reiterated its view that the key competitive advantages of PA Good Doctor over its
competitors are its large user traffic, strong AI and rising monetisation in online
medical services, rather than health mall. Going forward, it expects revenue from online
medical services to significantly outperform other business segments.
Daiwa expects gross profit contribution from online medical services to reach 80% by
2023. It raised its 2021-22 revenue by 12-17% due to its strong momentum in monetisation
of its core online medical services business, led by membership products. (KL)